Gilead signs deals with Indian companies for low-cost HIV drug

Thu Aug 2, 2012 7:19pm IST

Related Topics

Stocks

   

(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.

Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.

Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.

(Reporting by Shailesh Kuber; Editing by Viraj Nair)

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.

Reuters Showcase

Climate Change

Climate Change

U.S.-China climate deal does not put pressure on India, says Modi  Full Article 

Bangladesh Politics

Bangladesh Politics

Bangladesh charges opposition chief with instigating attack on bus  Full Article 

Ukraine Crisis

Ukraine Crisis

Rebels press Ukraine offensive, Obama promises steps against Russian-backed "aggression"  Full Article 

Australian Open

Australian Open

Sweet revenge for Murray as old guard hold firm   Full Article 

Box Office

Box Office

Eastwood's "American Sniper" continues as U.S. box office juggernaut   Full Article 

Boko Haram Fight

Boko Haram Fight

Nigeria repels suspected Boko Haram attack on Maiduguri city  Full Article 

Movie Review

Movie Review

Dolly ki Doli is a breezy watch, writes Shilpa Jamkhandikar.  Full Article | Related Story 

Akshay Kumar's Latest

Akshay Kumar's Latest

"Baby" is a smartly written, well-acted film  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage